The mission of Definium Therapeutics (formerly MindMed) is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future.
Company Profile
Industry Classifications
Sector
Healthcare
Industry
Biotechnology
Contact Information
Investor Relations
Gitanjali Jain
VP, Head of Investor Relations
gjain@definiumtx.com
Transfer Agent
Computershare Investor Services
100 University Ave.
8th Floor, North Tower
Toronto, Ontario M5J2Y1
Canada
T: 1-800-564-6253 (toll free in Canada and US)
F: 1-888-453-0330
Company Contact
Definium Therapeutics
One World Trade Center
Suite 8500
New York, NY 10007
United States
Offices
North Carolina Regional Office
Research Triangle Park
Durham, NC 27713
California Regional Office
Carmel Valley
San Diego, CA 92130